Protalix BioTherapeutics (PLX) Convertible Debt (2013 - 2023)
Protalix BioTherapeutics (PLX) posted quarterly Convertible Debt of $20.4 million for Q4 2023, down 27.56% year-over-year from $28.2 million in Q4 2022, and up 1.43% quarter-over-quarter from $20.1 million in Q2 2023.
Protalix BioTherapeutics (PLX) Convertible Debt (2013 - 2023) Analysis & Trends
Protalix BioTherapeutics' Convertible Debt history runs 11 years deep, the most recent figure standing at $20.4 million for Q4 2023.
- In Q4 2023, Convertible Debt fell 27.56% year-over-year to $20.4 million; the TTM figure through Dec 2023 stood at $20.4 million (down 27.56% YoY), while the FY2023 annual figure was $20.4 million, down 27.56% from the prior year.
- Convertible Debt for Q4 2023 stood at $20.4 million, up from $20.1 million in the prior quarter.
- The five-year high for Convertible Debt was $53.5 million in Q3 2020, with the low at $20.1 million in Q2 2023.
- The 5-year median for Convertible Debt is $28.2 million (2022), against an average of $37.1 million.
- The sharpest annual moves came in 2020 and 2021: Convertible Debt increased 6.66% in 2020, then slumped 48.01% in 2021.
- Protalix BioTherapeutics' Convertible Debt stood at $51.0 million in 2019, then gained by 5.0% to $53.5 million in 2020, then tumbled by 47.88% to $27.9 million in 2021, then grew by 1.08% to $28.2 million in 2022, then slipped by 27.56% to $20.4 million in 2023.
- Business Quant data shows PLX's Convertible Debt at $20.4 million in Q4 2023, $20.1 million in Q2 2023, and $28.3 million in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Protalix BioTherapeutics | 190.37 Mn | 149.71 Mn | 12.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 20.42 Mn |
| Jun 30, 2023 | 20.13 Mn |
| Mar 31, 2023 | 28.27 Mn |
| Dec 31, 2022 | 28.19 Mn |
| Sep 30, 2022 | 28.11 Mn |
| Jun 30, 2022 | 28.03 Mn |
| Mar 31, 2022 | 27.96 Mn |
| Dec 31, 2021 | 27.89 Mn |
| Sep 30, 2021 | 27.82 Mn |
| Sep 30, 2020 | 53.51 Mn |
| Jun 30, 2020 | 52.62 Mn |
| Mar 31, 2020 | 51.78 Mn |
| Dec 31, 2019 | 50.96 Mn |
| Sep 30, 2019 | 50.16 Mn |
| Jun 30, 2019 | 49.40 Mn |
| Mar 31, 2019 | 48.67 Mn |
| Dec 31, 2018 | 47.97 Mn |
| Sep 30, 2018 | 47.32 Mn |
| Jun 30, 2018 | 46.74 Mn |
| Mar 31, 2018 | 46.11 Mn |